Orphan drug hearing
Sen. Metzenbaum (D-Ohio) has scheduled an oversight hearing on high-priced, highly profitable orphan drugs before his Senate Judiciary/Antitrust Subcommittee for Jan. 21. Genentech, Amgen and Fujisawa are expected to be among the witnesses. Metzenbaum has asked that Sen. Kennedy (D-Mass.) subsequently schedule a legislative hearing before the Labor & Human Resources Committee on orphan drug amendments (S 2060), sponsored by Metzenbaum and Sen. Kassebaum (R-Kan.).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth